Sagimet Biosciences Inc. SEC Filings

Sagimet Biosciences Chief Financial Officer Thierry Chauche reported an automatic sale of Series A Common Stock largely tied to tax obligations. On February 10, 2026, he sold 1,312 shares at $5.3603 per share in an open-market transaction.

According to the disclosure, the shares were required to be sold to cover tax withholding arising from the vesting of restricted stock units, and the sales were automatic rather than discretionary. After this transaction, Chauche directly beneficially owned 15,688 shares of Sagimet Biosciences common stock.

Sagimet Biosciences’ Chief Medical Officer reports automatic share sale to cover taxes. Martins Eduardo Bruno sold 3,640 shares of Series A Common Stock on February 10, 2026 at an average price of $5.3602 per share in an open-market transaction.

According to the footnote, the sale was required to cover tax withholding obligations tied to vesting restricted stock units and was executed automatically, not at his discretion. After this transaction, he directly beneficially owned 103,296 shares of Sagimet Biosciences Inc.

Sagimet Biosciences Inc. Chief Legal & Admin. Officer Elizabeth Rozek reported an automatic sale of 2,622 shares of Series A Common Stock on February 10, 2026 at an average price of $5.3602 per share. After this tax-related sale, she beneficially owns 190,959 shares directly.

The shares were sold to cover tax withholding obligations arising from the vesting of restricted stock units, and the filing states that these sales were automatic and not made at her discretion.

Sagimet Biosciences Inc. filed a current report describing new communications to investors about a key development in its partnered acne program. The company issued a press release noting that Ascletis Pharma reported positive topline results from an open-label Phase 3 trial evaluating the long-term safety of ASC40 (denifanstat) tablets in patients with moderate to severe acne.

Sagimet also refreshed its investor slide presentation, which will be used in future investor meetings. Both the press release and the updated presentation are furnished as exhibits and are not treated as filed financial statements under securities law.

Sagimet Biosciences Inc. reported that it has updated its investor slide presentation and made it available as a new version for use in upcoming meetings with investors. The company also announced positive results from a Phase 1 pharmacokinetic trial evaluating a combination of its oral once-daily fatty acid synthase inhibitor, denifanstat, with a thyroid hormone receptor beta agonist, resmetirom. These early-stage data relate to how the drugs are processed in the body when used together and are being shared through a press release and updated investor materials attached as exhibits.

Sagimet Biosciences Inc. entered into a license agreement with Assia Chemical Industries Ltd., doing business as TAPI Technology & API Services, a subsidiary of Teva Pharmaceutical Industries. TAPI granted Sagimet a global, exclusive license to certain intellectual property covering innovative forms of TAPI’s resmetirom active pharmaceutical ingredient for Sagimet’s technical evaluation and manufacture.

If Sagimet elects to proceed after an evaluation period, the license also covers further development of a fixed-dose combination product containing denifanstat and resmetirom. Sagimet previously made a non-refundable up-front payment of $2.5 million to TAPI upon execution of a term sheet, and TAPI may be eligible for low single-digit royalties plus up to $5.5 million in additional manufacturing-related milestone payments. The agreement runs until specified TAPI know-how is no longer confidential or the last TAPI patent expires, unless terminated earlier under its terms.

Sagimet Biosciences Inc. (SGMT) reported an insider transaction by a director and Executive Chairman. On 11/20/2025, the reporting person sold 37,688 shares of Series A common stock in an open-market sale coded as "S." The weighted average sale price was $7.6942 per share, with individual trades executed between $7.27 and $8.15.

After this transaction, the insider beneficially owned 81,005 shares of Sagimet Biosciences common stock in direct ownership. The sale was carried out under a Rule 10b5-1 trading plan adopted on August 21, 2025, which is a pre-arranged plan designed to allow insiders to sell shares according to predetermined instructions.

Sagimet Biosciences (SGMT) furnished an update via Form 8-K. The company announced it issued a press release with financial results for the quarter ended September 30, 2025, and provided an updated investor presentation. Both materials are included as Exhibits 99.1 and 99.2 and are incorporated by reference.

The company noted that the press release and investor presentation are being furnished, not filed, under the Exchange Act. Representatives may use the updated presentation in meetings with investors.

Sagimet Biosciences (SGMT) reported Q3 2025 results showing a net loss of $12.9 million as it advances its fatty acid synthase inhibitor programs. Operating expenses were $14.3 million, with research and development of $9.7 million, down 23% year over year on lower Phase 3 denifanstat clinical costs, partly offset by a $2.5 million up-front CMO license fee and new early‑stage studies. General and administrative expenses were $4.6 million.

Liquidity remained solid with cash, cash equivalents and marketable securities of $125.5 million as of September 30, 2025, and management expects this to fund operations for at least the next 12 months. The company established a $75.0 million at‑the‑market program in August 2025 with no sales in the quarter. Accumulated deficit was $336.8 million.

Program updates: denifanstat met primary and multiple secondary endpoints in Phase 2b MASH and a Phase 1 PK trial combining denifanstat with resmetirom began in September 2025. In acne, Sagimet’s partner reported Phase 3 success in China and plans an NDA submission. Sagimet also began a Phase 1 trial of TVB‑3567 for acne in June 2025.